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The decline in the mortality specifically related to the
Human Immunodeficiency Virus (HIV) has revealed a
growing number of liver diseases, which are now one of
the leading causes of death among HIV-infected patients
treated with antiretroviral combinations. Liver diseases in
HIV-infected patients are usually secondary to hepatotox-
icity of antiretroviral treatments, metabolic syndrome and
lipodystrophy which may be associated with antiretrovi-
ral treatments, excessive alcohol consumption and co-
infection by one or several hepatotropic viruses. One of
the difficulties in the understanding of the liver enzymes
abnormalities is the potential intricacy of all the causes:
steatosis may be associated with hepatitis C infection,
especially genotype 3; alcohol chronic consumption is fre-
quently associated with HCV/HIV co-infection after an
history of intravenous drug use; hepatotoxicity of antiret-
roviral drugs is clearly increased by underlying liver dis-
ease whatever its cause, enhancing the direct toxicity of a
given drug or its metabolites. Recently, several cases of
unexplained liver disease in patients with a long history of
HIV infection, undetectable viral load and adequate
immune restoration have been reported. Nodular regener-
ative hyperplasia, defined by a diffuse transformation of
normal hepatic parenchyma into small, regenerative nod-
ules with little to no fibrosis, seems to account for an
unknown proportion of these cases. The mechanism of
HIV-associated nodular regenerative hyperplasia is, to
date, not known but does not seem to be related to HIV-
infection and acquired immunodepression per se since
the majority of patients are adequately immune-restored
under combined antiretroviral therapy. The obliteration
of the small portal veins results in ischemia of the sup-
plied acini and regenerative hyperplasia of the remainders
in order to maintain liver cell mass. We have reported that
the occurrence of anti-Protein S IgG antibodies in HIV-
infected patients leads to protein S deficiency that results
with time in a progressive obliteration of the small portal
venules of the liver, leading to obliterative venopathy and
compensatory nodular regenerative hyperplasia. The caus-
ative role of antiretroviral drugs and especially didanos-
ine, is difficult to assess. In summary, there are several
causes of liver abnormalities in HIV-infected patients
which require first to be recognised, second to be clearly
analyzed and third treated when possible. The initial liver
evaluation of any HIV-infected patient appears to be nec-
essary to better understand the future occurrence of liver
abnormalities. The place of non-invasive markers of fibro-
sis in this setting remains debatable.
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